Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit?

• References

• 1 Trifirò G, Corrao S, Alacqua M. et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006; 62: 582-590.
• 2 Li XQ, Andersson TB, Ahlstrom M. et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytoch-rome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
• 3 Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 2003; 63: 2739-2754.
• 4 Lau WC, Waskell LA, Watkins PB. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003; 107: 32-37.
• 5 Neubauer H, Günesdogan B, Hanefeld C. et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur Heart J 2003; 24: 1744-1749.
• 6 Serebruany VL, Midei MG, Malinin AI. et al. Absence of interaction between atorvastatin or other sta-tins and clopidogrel. Results from the INTERACTION study. Arch Intern Med 2004; 164: 2051-2057.
• 7 Gorchakova O, von Beckerath N, Gawaz M. et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-1902.
• 8 Saw J, Steinhubl SR, Berger PB. et al.. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
• 9 Wienbergen H, Gitt AK, Schiele R. et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-288.
• 10 Hollopeter G, Jantzen HM, Vincent D. et al. Identification of the platelet ADP receptor targeted by anti-thrombotic drugs. Nature 2001; 409: 202-207.
• 11 Chan FKL, Ching JYL, Hung LCT. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. New Engl J Med 2005; 352: 238-244.
• 12 Miner Jr P, Katz PO, Chen Y. et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-2620.
• 13 Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med 1981; 98: 591-598.
• 14 Kambayashi J, Shinoki N, Nakamura T. et al. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 1996; 81: 85-90.
• 15 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006; 295: 180-189.
• 16 Sibbing D, Morath T, Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
• 17 Lanas A, García-Rodríguez LA, Arroyo MT. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515.
• 18 Gellatly RM, Ackman ML. Single antiplatelet therapy for patients with previous gastrointestinal bleeds. Ann Pharmacother 2008; 42: 836-840.
• 19 Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23: 163-173.
• 20 Caruana JA, McCabe MN, Smith AD. et al. Risk of massive upper gastrointestinal bleeding in gastric bypass patients taking clopidogrel. Surg Obes Relat Dis 2007; 3: 443-445.
• 21 Toyoda K, Yasaka M, Iwade K. et al. Dual anti-thrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
• 22 Ng FH, Lam KF, Wong SY. et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-177.
• 23 Gilard M, Arnaud B, Cornily JC. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
• 24 Siller-Matula JM, Spiel AO, Lang IM. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5.
• 25 FDA.. 2007 safety alerts for drugs, biologics, medical devices, and dietary supplements: Omeprazole, omeprazole + sodium bicarbonate. August 9, 2007. http://www.fda.gov/medwatch/safety/2007/safety07.htm#Omeprazole
• 26 Bhatt DL, Scheiman J, Abraham NS. et al. ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
• 27 De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
• 28 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100 (Suppl. 03) 379-90.
• 29 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 30 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.